Section: Contact Information

First Name : **Jennifer** Last Name : **Yeh**

Institution: Boston Children's Hospital/Harvard Medical School

Address 1: 300 Longwood Avenue

Address 2 : City : **Boston**

State/Province/Region: MA
Country: United States
Zip/Postal Code: 02115
Phone Number: 8572185577
Alternate Phone Number:

Email Address: jennifer.yeh@childrens.harvard.edu

Section: Project Requirements and Description

Group: Requirements to submit AOI

A comprehensive review of previously published data has been completed. : Yes

The specific aims are clear and focused. : Yes

The investigator has appropriate experience and expertise to develop the concept proposal; if not, has identified a mentor or senior co-investigator. : **Yes**

The investigator agrees to develop an initial draft of the concept proposal within 6 weeks of approval of the AOI and to finalize the concept proposal within 6 months. : **Yes**

Project Title: Estimating the Clinical Outcomes and Cost-Effectiveness of Preventive Medicines to Reduce Secondary Cancers and Cardiovascular Disease in Childhood Cancer Survivors

Planned research population (eligibility criteria):

CCSS participants diagnosed between 1970 and 1999

Proposed specific aims:

Aim 1. Assess the clinical benefits, harms and harm-benefit tradeoffs of early initiation of tamoxifen to prevent breast cancer at 5-years from time of recognition of risk.

Aim 2. Evaluate the clinical benefits, harms and harm-benefit tradeoffs associated with aspirin for CRC prevention in at-risk survivors starting at younger ages.

Aim 3. Estimate the clinical benefits and harms associated with early initiation of aspirin for CVD and CRC prevention in at-risk survivors starting at younger ages.

Will the project require non-CCSS funding to complete? : Yes

If yes, what would be the anticipated source(s) and timeline(s) for securing funding? : I plan to submit a R01 application to NCI.

Group: Does this project require contact of CCSS study subjects for:

Additional self-reported information : No

Biological samples : **No**Medical record data : **No**

If yes to any of the above, please briefly describe. :

Group: What CCSS Working Group(s) would likely be involved? (Check all that apply)

Second Malignancy : **Secondary** Chronic Disease : **Primary**

Psychology / Neuropsychology : Secondary

Genetics:

Cancer Control:

Epidemiology / Biostatistics : Secondary

Section: Outcomes or Correlative Factors

Late mortality: Primary
Second Malignancy: Primary

Group: Health Behaviors

Tobacco: Alcohol:

Physical activity:
Medical screening:

Other:

If other, please specify:

Group: Psychosocial

Insurance:
Marriage:
Education:
Employment:
Other:

If other, please specify:

Group: Medical Conditions

Hearing/Vision/Speech : Hormonal systems :

Heart and vascular : Primary

Respiratory:
Digestive:

Surgical procedures:

Brain and nervous system:

Other:

If other, please specify:

Group: Medications

Describe medications:

Group: Psychologic/Quality of Life

BSI-18:

SF-36: Secondary

CCSS-NCQ:

PTS:

PTG:

If other, please specify:

Group: Other

Pregnancy and offspring:

Family history:

Chronic conditions (CTCAE v3): Primary

Health status:

Group: Demographic

Age: Secondary
Race: Secondary
Sex: Secondary

Other:

If other, please specify:

Group: Cancer treatment

Chemotherapy : Correlative Factors
Radiation therapy : Correlative Factors

Surgery: Correlative Factors

Section: Anticipated Sources of Statistical Support

CCSS Statistical Center: Yes Local institutional statistician:

If local, please provide the name(s) and contact information of the statistician(s) to be involved. :

Will this project utilize CCSS biologic samples? : No

If yes, which of the following?:

If other, please explain:

Section: Other General Comments

Other General Comments:

This proposal will use decision modeling to complete the proposed aims. CCSS data will be used to adapt existing simulation models for average-risk individuals to childhood cancer survivors (Aims 1 and 2). CCSS data will also be used to develop a simulation model of CVD and colorectal cancer among childhood cancer survivors (Aim 3).

I agree to share this information with St. Jude: Yes